Page last updated: 2024-12-08
cefcanel daloxate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
cefcanel daloxate: pro-drug to improve oral absorption of KY-087; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 179697 |
| SCHEMBL ID | 1230536 |
| MeSH ID | M0131973 |
Synonyms (17)
| Synonym |
|---|
| cefcanel daloxate |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (6r,7r)-7-[[(2r)-2-[(2s)-2-aminopropanoyl]oxy-2-phenylacetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| cefcanel daloxato [inn-spanish] |
| unii-d9693uhf82 |
| cefcanelum daloxatum [inn-latin] |
| 97275-40-6 |
| cefcanel daloxato |
| cefcanelum daloxatum |
| cefcanel daloxate [inn] |
| l-alanine, 2-((2-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)amino)-2-oxo-1-phenylethyl ester, monohydrochloride, (6r-(6alpha,7beta(r*)))- |
| 2,3-dihydroxy-2-butenyl (6r,7r)-7-((r)-mandelamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, cyclic 2,3-carbonate, ester with l-alanine |
| d9693uhf82 , |
| cefcanel daloxate [who-dd] |
| cefcanel daloxate [mart.] |
| SCHEMBL1230536 |
| Q27276258 |
| AKOS040745658 |
Research Excerpts
Overview
Cefcanel daloxate hydrochloride is a new oral cephalosporin prodrug.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cefcanel daloxate hydrochloride is a new oral cephalosporin prodrug. " | ( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994) | 2.03 |
| "Cefcanel daloxate is a new prodrug cephalosporin for oral use, with cefcanel as the antibacterially active principle. " | ( In vivo efficacy of cefcanel daloxate in comparison with cefaclor. Lionell, C; Magni, L, 1990) | 2.05 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Cefcanel renal clearance and fraction excreted in the urine were linearly correlated with renal function and thus, logarithmic increases in plasma area under the concentration versus time curve and plasma elimination half-life were seen with decreasing GFR." | ( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994) | 0.59 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The absolute oral bioavailability of cefcanel was approximately 40% after administration of cefcanel daloxate hydrochloride and the extent of urinary excretion of cefcanel, mandelic acid glycine conjugate, and N-mandelyl-2-aminoethanol after an equimolar intravenous administration of cefcanel, were determined in a separate, similar group of volunteers (N = 12, group B)." | ( Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. Arvidsson, A; Edwall, B; Lake-Bakaar, D; Lanbeck-Vallén, K; Yisak, W, ) | 0.65 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although steady state kinetics were not performed our findings suggest that a dosage reduction is not necessary even in pre-uraemic patients." | ( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994) | 0.59 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||